SEEL
Income statement / Annual
Last year (2023), Seelos Therapeutics, Inc.'s total revenue was $2.20 M,
and the percentage change from the previous year is not available.
In 2023, Seelos Therapeutics, Inc.'s net income was -$37.88 M.
See Seelos Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.20 M
|
$0.00
|
$0.00
|
$0.00
|
$375,000.00
|
$0.00
|
$0.00
|
$5.76 M
|
$4.84 M
|
$9.26 M
|
| Cost of Revenue |
$30.12 M |
$53,000.00 |
$0.00 |
$0.00 |
$22.56 M |
$0.00 |
$117,000.00 |
$3.89 M |
$922,000.00 |
$918,000.00 |
| Gross Profit |
-$27.91 M |
-$53,000.00 |
$0.00 |
$0.00 |
-$22.19 M |
$0.00 |
-$117,000.00 |
$1.87 M |
$3.92 M |
$8.34 M |
| Gross Profit Ratio |
-12.67 |
0 |
0 |
0 |
-59.17 |
0 |
0 |
0.32 |
0.81 |
0.9 |
| Research and Development
Expenses |
$30.12 M
|
$58.62 M
|
$46.65 M
|
$10.98 M
|
$22.56 M
|
$1.22 M
|
$3.46 M
|
$6.83 M
|
$14.65 M
|
$21.29 M
|
| General & Administrative
Expenses |
$12.59 M
|
$12.30 M
|
$15.02 M
|
$7.78 M
|
$7.56 M
|
$7.93 M
|
$7.21 M
|
$8.43 M
|
$10.52 M
|
$11.42 M
|
| Selling & Marketing
Expenses |
-$57,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.53 M
|
$12.30 M
|
$15.02 M
|
$7.78 M
|
$7.56 M
|
$7.93 M
|
$7.21 M
|
$8.43 M
|
$10.52 M
|
$11.42 M
|
| Other Expenses |
$0.00 |
-$3.02 M |
$230,000.00 |
$0.00 |
-$375,000.00 |
$1,000.00 |
$77,000.00 |
-$22,000.00 |
-$64,000.00 |
$82,000.00 |
| Operating Expenses |
$12.59 M |
$70.92 M |
$61.67 M |
$18.76 M |
$29.75 M |
$9.15 M |
$10.67 M |
$15.27 M |
$25.17 M |
$30.90 M |
| Cost And Expenses |
$42.70 M |
$70.92 M |
$61.67 M |
$18.76 M |
$29.75 M |
$9.15 M |
$10.67 M |
$19.16 M |
$26.09 M |
$31.82 M |
| Interest Income |
$198,000.00 |
$121,000.00 |
$113,000.00 |
$45,000.00 |
$151,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$75,000.00 |
$14,000.00 |
$1.60 M |
$164,000.00 |
$29,000.00 |
$0.00 |
$83,000.00 |
$1.02 M |
$845,000.00 |
$339,000.00 |
| Depreciation &
Amortization |
$57,000.00
|
$53,000.00
|
$61.67 M
|
$18.76 M
|
$41,000.00
|
$41,000.00
|
$117,000.00
|
$106,000.00
|
$300,000.00
|
$170,000.00
|
| EBITDA |
-$37.75 M
|
-$73.47 M
|
$0.00
|
$0.00
|
-$29.33 M
|
-$3.14 M
|
-$10.56 M
|
-$6.11 M
|
-$17.83 M
|
-$21.97 M
|
| EBITDA Ratio |
-17.14 |
0 |
0 |
0 |
-78.21 |
0 |
0 |
-2.36 |
-4.34 |
-2.44 |
| Operating Income Ratio
|
-18.38
|
0
|
0
|
0
|
-79.33
|
0
|
0
|
-2.33
|
-4.41
|
-2.44
|
| Total Other
Income/Expenses Net |
$2.62 M
|
-$2.62 M
|
-$4.38 M
|
-$342,000.00
|
-$21.51 M
|
$5.74 M
|
-$1.08 M
|
$5.96 M
|
$2.33 M
|
$82,000.00
|
| Income Before Tax |
-$37.88 M |
-$73.53 M |
-$66.05 M |
-$19.10 M |
-$50.88 M |
-$9.22 M |
-$11.75 M |
-$7.43 M |
-$19.02 M |
-$22.48 M |
| Income Before Tax Ratio
|
-17.2
|
0
|
0
|
0
|
-135.68
|
0
|
0
|
-1.29
|
-3.93
|
-2.43
|
| Income Tax Expense |
$0.00 |
$2.60 M |
$1.49 M |
$119,000.00 |
-$497,000.00 |
-$70,000.00 |
-$11.91 M |
$1.00 M |
$781,000.00 |
-$691,000.00 |
| Net Income |
-$37.88 M |
-$76.14 M |
-$67.53 M |
-$19.22 M |
-$50.38 M |
-$9.24 M |
$321,000.00 |
-$7.43 M |
-$19.02 M |
-$21.79 M |
| Net Income Ratio |
-17.2 |
0 |
0 |
0 |
-134.35 |
0 |
0 |
-1.29 |
-3.93 |
-2.35 |
| EPS |
-7.73 |
-21.48 |
-22.29 |
-12.88 |
-74.43 |
-89.97 |
24.32 |
-67.41 |
-3442.83 |
-165 |
| EPS Diluted |
-7.73 |
-21.48 |
-22.29 |
-12.88 |
-74.43 |
-89.97 |
24.32 |
-67.41 |
-3442.83 |
-165 |
| Weighted Average Shares
Out |
$4.90 M
|
$3.54 M
|
$3.03 M
|
$1.49 M
|
$676,960.00
|
$102,718.00
|
$13,200.00
|
$110,267.00
|
$5,525.40
|
$132,035.00
|
| Weighted Average Shares
Out Diluted |
$4.90 M
|
$3.54 M
|
$3.03 M
|
$1.49 M
|
$676,960.00
|
$102,718.00
|
$13,200.00
|
$110,267.00
|
$5,525.40
|
$132,035.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
